Consensus: Rational approach towards the patient with cancer, fever and neutropenia;Consenso: Manejo racional del paciente con cáncer, neutropenia y fiebre

Revista Chilena de Infectologia

Volumn 22, Issue SUPPL. 2, 2005, Pages

  De Maria Elena Santolaya P ^a,e   Ricardo Rabagliati, B ^a   Teresa Bidart, H ^a   Ernesto Paya G ^a   Ana M Guzman D ^a   Ricardo Morales, I ^a   Stephanie Braun, J ^a   Lucia Bronfman F ^a   Marcela Ferres G ^a   Claudio Flores, P ^a   Patricia Garcia C ^a   Luz M Letelier, S ^d   Barbara Puga L ^c   Carmen Salgado, M ^b   Luis Thompson, M ^a   Juan Tordecilla, C ^b   Marcela Zubieta, A ^a  

^a Sociedad Chilena de Infectología ^*

^b Programa Infantil Nacional de Drogas Antineoplásicas PINDA

^c Programa Adulto Nacional de Drogas Antineoplásicas PANDA

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e Unidad de Medicina Basada en Evidencia Pontificia Universidad Católica de Chile ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BACTERIAL INFECTION; FEVER; HUMAN; NEOPLASM; NEUTROPENIA; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT;

EID: 55449083525     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (175)

1. Pizzo P A, Robichaud K J. Wesley R, Commers J R. Fever in the pediatrie and young adult patient with cancer: A prospective study of 1001 episodes. Medicine 1982; 61: 153-65.
2. Bodey G P. Buckley M. Salhe Y S. Freireich E J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
3. Schimpff S, Satterlce W, Young V M, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284: 1061-5.
4. Hughes W T, Armstrong D, Bodey G P, Bow E J, Brown A E, Calandra T, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
5. Glauser M P. Calandra T. Infections in patients with hematologic malignancies. In: Glauser M P, Pizzo P A, eds. Management of Infections in Immunocompromised Patients. London: WB Saunders ed; 2000; 141-88.
6. Segal B, Walsh T, Holland S. Infections in the cancer patient. In: DeVita V, Hellrnan S, Roscnberg S, eds. Cancer. Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins ed; 2001; 2815-68.
7. Marchetti O, Calandra T. Infections in neutropenic cancer patients. Lancet 20002; 359: 723-5.
8. Bochud P Y, Calandra T, Francioli P. Bacterernia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97: 256-64.
9. Cometta A. Calandra T, Bille J, Glauser M. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240-1.
10. Cruciani M. Rampazzo R. Malena M, Lazzarini L, Todeschini G, Messori A, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23: 795-805.
11. Payá E. Álvarez A, Avilés C, Cofré J, Enríquez N. Salgado C. et al. Agentes causantes de infecciones del torrente circulatorio en niños con ćancer, en cinco hospitales de Santiago (1994-1998). Rev Méd Chile 2001; 129: 1297-304.
12. Sanlolaya M E. Álvarez A, Becker A. Cofré J, Enríquez N, O 'Ryan M, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol 2001 19: 3415-21.
13. Santolaya M E, Álvarez A M, Avilés C L, Becker A. Cofré J, Enríquez N, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, lever and neutropenia, Clin Infect Dis 2002; 35: 678-83,
14. Puga B, Puga I, Cabrera M E, Undurraga M S, Guerra C, Urrcjola G, et al. Neutropenia febril de alto riesgo en leucemia aguda. Experiencia en un hospital públieo. Programa naeional de drogas antineoplásicas del adulto (PANDA). Hospital del Salvador, 1991-2001. Rev Med Chile 2003; 131: 1023-30.
15. Rarnos G, Domínguez I, Benítez R, Guzmán A M, García P, Sánchez T, et al. Etiología de bacleriemias en neutropenia febril de pacientes adultos con cáncer. Hospital Clínico Univcrsidad Catélica 2001-2004. Libro ro de Resúmenes. XXI Congreso Chileno de Infcctología. Viña del Mar 13-16 de octubre 2004. Pág 42. resumen CO1.
16. Klastersky J, Paesmans M, Rubenstein E B, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients, J Clin Oncol 2000; 18: 3038-51.
17. Rabagliati R, Benítez R, Domínguez I, Ramos G, Ocquetau M. Álvarez M. Perfil clínico y categorización de riesgo de episodios de neutropenia febril en pacienles adultos con cáncer. Libro de Resúmenes. XXI Congreso Chileno de Infectología. Vina del Mar 13-16 de octubre 2004. Pág 42, resumen CO2.
18. Morales R, Rojas L, Palma S, Donaire L, Beltrán C, Muñoz L. Análisis descriptive de 74 episodios de neutropenia febril en adultos. Hospital Harros Luco Trudeau. Libro de Resúmenes. XXI Congreso Chileno de Infectología. Viña del Mar 13-16 de octubre 2004. Pág 43, resumen CO3.
19. Bustos M, Rojas L, Rojas C. Braun S, Rubio G. Caracterización de pacientes portadores de neoplasia hematológica sometidos a quimioterapia que cursan eon neutropenia febril en un hospital de Santiago. Libro de Resúmenes. XXI Congreso Chilene de Intectología. Viña del Mar. 13-16 de oclubre 2004, Pag 43, resumen CO4.
20. Chang H Y, Rodríguez V, Narboni G, Bodey G P, Luna MA, Freireich E J. Causes of death in adults with acute leukemia. Medicine (Baltimore) 1976; 55: 259-68.
21. Wingard J R. Merz W G, Rinaldi M G, Johnson T R. Karp J E, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole, N Engl J Med 1991; 325: 1274-7.
22. White M H. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 1997; 24: 1129-30.
23. Sepkowitz K A. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34: 1098-107.
24. Hughes W T, Fcldman S. Aur R J, Verzosa M S, Hustu H O. Simone J V. Intensity of immunosuppressive therapy and the incidence of Pneumocysits carinii pneumonitis. Cancer 1975; 36: 2004-9.
25. Sepkowitz K A. Brown A E, Telzak E E, Gottlieb S. Armstrong D. Pneumocysits carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267: 832-7.
26. Lucero Y. Brucher R. Álvarez A M. Becker A, Cofré J, Enríqucz N. et al. Infección micótica profunda en niños con cáncer, neutropenia y fiebre, en Chile. Rev Méd Chile 2002; 130: 1139-46.
27. Wood M J. Viral infections in neutropenia-currents problems and chemotherapeutic control. J Antimicrob Chemother 1998; 41 Suppl D: 81-93.
28. Santolaya M E, Cofré J. Beresi V. C-reactive protein: A valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis 1994; 18: 589-95.
29. Bodey G, Bueltmann B, Duguid W. Gibbs D, Hanak H, Hotchi M, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
30. Comely O A, Schirmacher P. Clinical picture: Bacterial translocation in neutropenic sepsis. Lancet 2001; 358: 1842.
31. Fatkenhcucr G. Buchheidt D. Comely O A. Fuhr H G, Karthaus M, Kisro J, et al. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Central venous catheter (CVC)-related infections in neutropenic patients- Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82: S149-57.
32. Paisley J, Lauer B. Pediatrie blood cultures. Clin Lab Med 1994; 14: 17-30.
33. Blot F. Nitenber G, Chachaty E, Raynard B, Germann N, Antoun S, et al. Diagnosis of catheterrelated bacteraemia: prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 1999; 354: 1071-7.
34. Rijners B J, Verwaest C, Peetermans W E. Wilmer A. Vandecasteele S, Van Eldere J, et al. Difference in time to positivity of hub-blood versus nonhub-blood cultures is not useful for the diagnosis of catheterrelated bloodstream infection in critically ill patients. Crit Care Med 2001; 29: 1399-403.
35. Raad I, Hanna H, Alakech B, Chatzinikolaou I, Jonson M. Tarrand J. Differential time to positivity: a useful method for diagnosing catheter related bloodstream infections. Ann Intern Med 2004; 140: 18-25.
36. Seifert H, Comely O. Seggewiss K, Decker M. Stefanik D. Wisplinghoff H, et al. Bloodstream infection in neutropcnic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular cpidemiological typing with pulsed-field gel electrophorcsis. J Clin Microbiol 2003; 41: 118-23.
37. Donowitz G R, Maki D G, Cmich C J, Pappas P G. Rolston K V. Infections in the neutropenic patient - new views of an old problem. Hematology (Am Soc Hcmatol Edu Program) 2001; 1 13-39.
38. Capdevila JA, Planes A M, Palornar M. Gasser I, Almirante B. Pahissa A et al. Value of differential quantitative blood cultures in the diagnosis of catheterrelated sepsis. Eur J Clin Microb Infect Dis 1992; 1 1: 403-7.
39. Quilici N, Audibert G, Conroy M C, Bollaert P E, Guillemin F. Welfringer P, et al. Differencial quantitative blood cultures in the diagnosis of catheterrelated sepsis in intensive care units. Clin Infect Dis 1997; 25: 1066-70.
40. Gerain J, Sculier J P, Malengreaux A, Rykaert C, Themelin L. Causes of death in an oncologic intensive care unit: clinical and pathological study of 34 autopsies. Eur J Cancer 1990; 26: 377-81.
41. McDonald L C, Weinstein M P, Fune J, Mirrett S, Reimer L G, Relier L B. Controlled comparison of BacT/ALERT FAN aerobic medium and BACTEC fungal blood culture medium for detection of fungemia. J Clin Microbiol 2001; 39: 622-4.
42. Donnelly J.P. Symptoms and diagnosis of nosocomial fungal infections-State of the Art. Eur J Med Res 2002; 7: 192-9.
43. Maschmeyer G, Beinerl T, Buchheidt D. Einsele H, Heussel C P. Kiehl M, et al. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hernatol 2003; 82: SI 18S26.
44. Labarca J, Hervé B, Fica A, Arancibia F, Ruiz M, Yunge M. Consenso nacional de neumonía asociada a ventilación mecánica. Diagnóstico. Rev Chil Infect 2001; 18: 539-40.
45. Monheit J, Cowan D, Moore D. Rapid detection of fungi in tissues using calcofluor white and fluorescent microscopy. Arch Pathol Lab Med 1984; 108: 616-8.
46. García P, Beltrán C, Guzmán A M, Leon P, Arredondo M, Fonscca X. Diagnóstico rápido de dos casos de mucormicosis con tinción de blanco de calcoflúor. Rev Chil Infect 2001; 18: 285-90.
47. Kovacs J A, Ng V L, Masur H, Leoung G, Hadley W K, Evans G. et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med 1988; 318: 589-93.
48. Cregan P, Yamamoto A, Lum A, Van der Heide T, MacDonald M. Pulliam L. Comparison of four methods for rapid detection of Pneumocyxtis carinii in respiratory specimens. J Clin Microbiol 1990; 28: 2432-6.
49. Sandven P, Lassen J. Importance of selective media for recovery of yeast from clinical specimens. J Clin Microbiol 1999; 37: 3731-2.
50. Maertens J, Verhacgen J, Demuynck H. Brock P, Verhoef G. Vandenberghe P. et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactornannan by a sandwich enzyme-linked imrnunosorbent assay for haematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-8.
51. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F et al. Aspergillus galactornannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-906.
52. Ascioglu S, Rex B, Bennett J E, Bille J. Crokaerl D. Denning J P, et al. Defining opportunistic invasive fungal infections in irnmunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 714.
53. Ison M. Viral infections in irnmunocompromised patients: what is new with respiratory viruses? Curr Opin Infect Dis 2002; 15: 355-67.
54. Echavarria M. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358 (9279): 384-5.
55. Hamelin M E, Abed Y. Boivin G. Human metapncumovirus: a new player among respiratory viruses. Clin Infect Dis 2004; 38 (7): 983-490.
56. Storch G A. Viral Infections in Irnmunocompromised Patients. En: Storch G A. Essentials in Diagnostic Virology. Churchill Livingston Ed, 2000; 203-32.
57. Coria P. Mamani N. O'Ryan M, Vidai R, Noemí I. Mosso C. et al. Diarrea aguda en niños con cáncer y neutropenia febril. Libro de Resúmenes. XXI Congreso Chilcno de Infectología, Vina del Mar. 13-16 de octubrc 2004. Pág 76. resumcn CO49.
58. Gómez L, Martino R, Rolston K V. Neutropcnic enterocolitis: spectrum of the disease and comparison of definitive and possible cases. Clin Infect Dis 1998; 27: 695.
59. Giamarellou H, Antoniadou A. Infectious complications of febrile leucopcnia. Infcc Dis Clin North Am 2001; 15: 457-82.
60. Lopez F, Sanders CV. Dermatologie infections in the irnmunocompromised (non-HIV) host. Infect Dis Clin North Am 2001; 15: 671-702.
61. Elting L S, Rubenstcin E B, Rolston K. Bodey G P. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-59.
62. Talcott J, Finberg R, Maycr R, Goldman L. The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1988; 148: 2561-8.
63. Talcott J, Siegel R. Finberg R, Goldman L. Risk Assessment in cancer patients with fever and neutropenia: A prospective, two-validation of a prediction rule. J Clin Oncol 1992; 10: 316-22.
64. Kem W V. Risk assessment and risk-based therapeutic strategics in febrile neutropenia. Curr Opin Infect Dis 2001; 14: 415-22
65. von Lilienfeld-Toal M, Sievers E. Bodemuller V. Mihailescu C, Marten A. Gorschluter M. et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactivc protein. Eur J Clin Microbiol Infect Dis 2004; 23: 539-44.
66. Hann I, Viscoli C. Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997; 99: 580-8.
67. Rackoff W, Gonin R. Robinson C. Kreissman S, Breitfeld P. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-24.
68. Klaasscn R J. Goodman T R, Pham B, Doyle J J. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-9.
69. a ed. Mandell GL. Bennett JE, Dolin R, eds. Churchill Livingslone 2004; 3102-11.
70. Schimpff S C, Hahn D M . Brouillel M P. Young V M. Fortner C L, Wiener P H. Infection prevention in acute leukemia: Comparison of basic infection prevention techniques, with standard room, reverse isolation or with reverse isolation plus added air filtration. Leuk Res 1978; 2: 231-40.
71. Levine A S, Siegel S E, Schreiber A D, Hauser J, Preisler H, Goldstein I M, et al. Protect environment and prophylactic antibiotic. A prospective controlled studying of their utility in the therapy of acute leukemia. N Engl J Med 1973; 288: 477-83.
72. Rodríguez V, Bodey G P, Freireich E J, McCredie K B, Gutterman J U, Keating M J, et al. Randomized trial of protected environment prophylactic antibiotic in 145 adults with acute leukemia. Medicine (Baltimore) 1978; 57: 253-66.
73. Nauseef W M, Maki D G. A study of the value of simple vs protective isolation in patients with granulocytopenia. N Engl J Med 1981; 304: 448-53.
74. Garner J S and the Hospital Infection Control Practices Advisory Committee. Guidelines for Isolation Precautions in Hospitals. From the Public Health Service, US Department of Health and Human Services. Centers for Disease Control and Prevention, Atlanta. Georgia. 2004. disponible en URL: http://www.cdc.gov/ncidod/ hip/ISOLAT/Isolat.htm (aecedido en mayo 12, 2004)
75. Boyce J M, Pittet D; Healthcare Infection Control Practices Advisory Committee; HICPAC/SHEA/APIC/ IDSA Hand Hygiene Task Force. Guidelines for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/ APIC/IDSA Hand Hygiene Task Force. Am J Infect Control 2002; 30: S1-46.
76. Knittle M A, Eitzman D V, Baer H. Role of hand contamination of personnel in the epidemiology of gram-negative nosocornial infections. J Pediatr 1975; 86: 433-7
77. Larson E, Mayur K, laughon B A. Influence of two handwashing frequencies on reduction in colonizing flora with three handwashing products used by health care personnel. Am J Infect Control 1989; 17: 83-8.
78. Garner J S. Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices. Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996; 24: 24-31.
79. Garner J S. Guideline for isolation precautions in hospitals. Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996; 24: 3252.
80. Comité Nacional de Infectología de la Sociedad Argentina de Pediatría. Consenso Nacional. Riesgo de infección en el paciente oncológico. Arch Arg Pediatría 2003; 101: 270-95.
81. Paugam A, Renaud B, Bousset B, Salmon D, Dupouy Carnet J. Contribution of air mycological control for the prevention of invasive aspergillosis. Pathol Biol Paris 1997; 45: 410-3.
82. Sánchez-Payá J. Prevención de la aspergilosis nosocornial. Rev Iberoam Micol 2000; 17: S100-2.
83. Nolard N. Links between risks of aspergillosis and environmental contamination. Review of the literature. Pathol Biol (Paris) 1994; 42: 706-10.
84. Loo V G, Bertrand C, Dixon C, Vitye D, DeSalis B, McLcan A P. Control of construction associated nosocornial aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 1996; 17: 360-4.
85. Opal S M, Asp A A, Cannady P B Jr, Morse P L, Burton L J, Hammer P G 2nd. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 1986; 153: 634-7.
86. Paganini H, Sarkis C, De Martino M. Zubizarreta P. Casimir L, Fernández C. et al. Oral administration of cefixime to lower risk febrile ncutropenic children with cancer. Cancer 2000; 88: 2848-52.
87. Shenep J L, Flynn P M, Baker D K, Heiherington S V, Hudson M M, Hughes W T, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile ncutropenic children with cancer. Clin Infect Dis 2001; 32: 36-43.
88. Paganini H. Rodriguez-Brieshcke T, Zubizarreta P. Latella A. Firpo V, Casismir L. et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 2001; 91: 1563-7.
89. Paganini H, Gomez S, Ruvisky S, Zubizarreta P. Latella A. Fraquelli L, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 2003; 97: 1775-80.
90. Freifeld A. Pizzo P. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatrie cancer patients. Pediatr Infect Dis J 1997; 16: 140-6.
91. Kern W V, Cometta A, DeBock R, Langenacken J. Paesmans M. Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312-8.
92. Freifeld A, Marchigiani D. Walsh T, Chanock S, Lewis L, Hiemenz J, A double-blind comparison of empirical oral or intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy N Eng J Med 1999; 341: 305-11.
93. Comely O A, Wicke T, Seifert H, Bethe U, Schwonzen M. Reichert D, et al. Once daily oral levofloxacin monotherapy versus piperacillin/ tazobactam three times a day: a randomized controlled multiccntcr trial in patients with febrile neutropenia. Int J Hematol 2004; 79: 74-8.
94. Vidai L, Paul M, Ben dor I. Soares-Weiser K. Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and mcta-analysis of randomized trials. J Antimicrob Chemother 2004; 54: 29-37.
95. Santolaya M E, Álvarez A M, Avilés C L, Becker A, Cofré J, Cumsille M A, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 2004; 22: 3784-9.
96. Hidalgo M. Hornedo J, Lumbreras C, Trigo J M, Colomcr R, Pcrea S, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. Cancer 1999; 85: 213-9.
97. Malik IA, Khan W A, Karim M, Aziz Z. Khan M A. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995; 98: 224-31.
98. Fumo P, Dionisis M S, Bucaneve M, Menichetti F. Del Favero A, Ceftriaxone versus beta-laclams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a metaanalysis. Support Care Cancer 2000; 8: 293-301.
99. Paul M, Soarez-Eiser K, Grozinski S, Leibovici L. βlactam versux β-lactam-aminoglycosidc combination therapy in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichesler, UK: John Wiley & Sons, Ltd.
100. Tamara K, Imajo K, Akiyama N, Suzuki K, Urabe A. Ohyashiki K, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 2004; 39: S15-24.
101. Raad I I, Escalante C, Hachem R Y, Hanna H A. Husni R. Afif C, Boktour M R, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003; 98: 1039-47.
102. Fleischhack G. Hartmann C, Simon A, Wulff B, Havers W. Marklein G, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemolher. 2001; 47: 841-53.
103. Biron P. Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, et al. Cefepime versus imipcnem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 1998; 42: 511-8.
104. Perez C, Sirham M, Labarca J, Grebe G, Lira P, Oliva J. Imipenem/cilastatin versus ceftazidima-amikacina en el tratamiento de pacientes neutropénicos febriles. Rev Méd Chile 1995; 123: 312-20.
105. Del Favero A, Menichetti F, Martino P, Bucancve G, Micozzi A, Gentile G, et al. A multicenter, doubleblind, placebo-controlled trial comparing piperacillintazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-301.
106. Johnson P R. Yin J A, Tooth T A. High dose intravenous ciprofloxacin in febrile neutropenic patients. J Antimicrob Chemoter 1990; 26 Suppl F: 101-7.
107. Meunier F, Zinner S H, Gaya H, Calandra T, Viscoli C, Klastersky J. et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empirical antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother 1991; 35: 873-8.
108. Furno P, Bucancve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-42.
109. Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A. Ohyashiki K, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 2004; 39: S15-24.
110. Ohyashiki K. Monotherapy ver.yus dual therapy based on risk categorization of febrile neutropenic patients. Clin Infect Dis 2004; 39: S56-8.
111. o RR-12): 1-13.
112. Elting L S, Rubenstein E B, Rolston K, Cantor S B, Martin C G, Kurtin D, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropcnia with implications for quality and cost of care. J Clin Oncol 2000; 18: 3699-706.
113. Petrilli A S, Dantas L S, Campos M C, Tanaka C, Ginani V C. Seher A. Oral ciprofloxacin v.v intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatrie oncology patients: randomized prospective trial. Med Pediatr Oncol 2000; 34: 87-91.
114. Santolaya M E, Álvarez A M, A viles C L. Becker A, Cofré J, Paya E. Tratamicnto selective de los episodios de neutropenia febril en niños con cáncer. Comité de Infectología, Programa Infantil Nacional de Drogas Antineoplásicas (PINDA) Rev Chil Infect 2004; 21: 213-22.
115. Santolaya M E, Villarroel M, Avcndaño L, Cofré J. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: A prospective study. Clin Infect Dis 1997; 25: 92-7.
116. Pizzo P A. Robichaud K J, Gill F A, Witebsky F G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-11.
117. EORTC International Antimicrobial Therapy Cooperative Project Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-72.
118. Bennett J E, Kauffman C. Walsh T, de Pauw B, Dismukes W, Galgiani J, et al. Forum Report: Issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36 Suppl 3: SI 17-22.
119. Pappas P G, Rex J H, Sobel J D, Filler S G, Dismukes W E, Walsh T J. et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
120. Lin M, Lu H, Chcn W L. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 2001; 33: 1621-7.
121. Macrtens J, Verhaegen J, Lagrou K, Van Eidere J, Boogacrts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patient and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-10.
122. Bcnitez R. Ramos G, Domínguez I. Guzrnan AM, Castillo C, Rabagliati R. Experiencia del uso del test de detección de antigeno de galactomanana sérico en el proceso diagnóstico de aspergilosis pulmonar invasora en pacientes adultos con patologia hematooncoiógica. Lihro de Resúmenes XXI Congreso Chileno de Infectología. Vina del Mar, 13-16 de octubre 2004. Pag 93, Resumen CO82.
123. Gotzsche P C, Johanscn H K. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochranc Review) The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons Ltd.
124. Walsh T J. Finberg R W, Arndt C, Hicmcnz J, Schwartz C, Bodentcincr D, ct al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-71.
125. Malik I A, Moid I, Aziz Z. Khan S. Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Amer J Med 1998; 105: 478-83,
126. Viscoli C. Castagnola E, Van Lint M T, Moroni C, Garaventa A. Rossi M R, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, mullicentre, prospective and randomized clinical trial. Eur J Cancer 1996; 32A: 814-20.
127. Winston D J, Hathorn J W, Schuster M G, Schiller GJ, Territo M C. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neulropenic patients with cancer. Am 1 Med 2000; 108: 282-9.
128. Suva V, Díaz. M C, Febré N. Red de diagnóstico en micología médica. Vigilancia de la resistencia de levaduras a antifungicos. Rev Chil Infect 2002; 19 Supl 2: S149-56.
129. Boogaerts M. Winston D J, Bow E J, Garbcr G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycolate as empirical antifungal therapy l'or persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A ramdomized, controlled trial. Ann Intern Med 2001; 135: 412-22.
130. Pica A. Tratamiento de infecciones fúngicas sistémicas. Primera parte: fluconazol, itraconazol y voriconazol. Rev Chil Infect 2004; 21: 26-38.
131. Walsh T J, Pappas P, Winston D J. Lazarus H M, Pelersen F, Ratffalli J. et al. Voriconazol compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
132. Powers J H, Dixon C A, Goldberger M J. Voriconazolc versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 289-90.
133. Walsh T J. Pappas P, Winston D J, Lazarus H M. Petersen F, Raffalli J. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy (reply). N Engl J Med 2002; 346: 1745-7.
134. Walsh T, Teppler H, Donowits G, Maertens J, Baden L, Dmoszynska A. et al. Caspofungin v.v liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
135. Herbrccht R, Denning D W, Petterson T F. Bennett J E. Greene R G, Oestmann J W. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
136. Maertens J, Raad I, Petrikkos G, Sellcslag D, Petersen F, Sable C, et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to others antifungal agents: analysis of 90 patients. Program and Abstracts of the 42th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002 San Diego, USA: 388 (abstr M-686).
137. Del Favero A. Management of fungal infections in neutropenic patients: more doubts than certainties? Int J Antimicrob Agents 2000; 16: 135-7.
138. Bow E J. Laverdiere M, Lussier N, Rotstein C. Cheang MS, loannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients. A meta-analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
139. 139.-Hughes W T, Armstrong D, Bodey G P. Brown A E, Edwards J E, Feld R, et al. 1997 Guidelines lor the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551-73.
140. Hidalgo M. Hornedo J, Lumbreras C. Trigo J M. Gornez C, Perea S, et al. Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Antimicrob Agents Chemother 1997; 41: 1175-7.
141. Engels E A, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a metaanalysis. J Clin Oncol 1998; 16: 1179-87.
142. Munoz L, Martino R, Subira M, Brunei S, Sureda A. Sierra J. Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe shortduration neutropenia in patients with lymphoma. Leuk Lymphoma 1999; 34: 585-9.
143. Zinner S H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490-4.
144. Raje N S Rao S R, lyer R S, Kelkar R S, Pai S K, Nair C N. Kurkure P A, et al. Infection analysis in acute lymphoblastic leukemia: a report of 499 consecutive episodes in India. Pediatr Hematol Oncol 1994; 11: 271-80.
145. Kern W V Andriof E, Oethinger M. Kcm P. Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38: 681-7.
146. EORTC Trimethoprim-sulfamethoxazolc in the prevention of infection in
147. Kerr K G. The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemother 1999; 44: 587-91.
148. Tjan-Heijnen V C. Postmus P E, Ardizzoni A, Manegold C H, Burghouts J, van Meerbeeck J. et al. European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofioxacin and roxithromycin in small-cell lung cancer patients: an EORTC doubleblind placebo-control led phase III study. Ann Oncol 2001; 12: 1359-68.
149. Castagnola E, Boni L. Giacchino M, Cesaro S, De Sio L. Garaventa A, et al. Infectious Diseases Study Group of the Italian Association of Pediatrie Hematology and Oncology. A multicenter. randomized, double blind placebo-controlled trial of amoxicillin/ clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J 2003; 22: 359-65.
150. Jimenez Martínez C, Ribera Santasusana J M, Giméncz Ṕerez M, Battle Masana M, Flores López A. FcrnándezAviles F. et al. Prevention and treatment of infections in patients with neutropenia and fever: the role of Pxeudomonas aeruginoxa. Rev Clin Esp 1998; 198 Suppl 2: 44-50.
151. Cruciani M, Rampazzo R. Malena M, Lazzarini L. Todeschini G. Messori A, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patienls: a mela-analysis. Clin Infect Dis 1996; 23: 795-805.
152. Cruciani ML Antibacterial prophylaxis. Int J Antimicrob Agents 2000; 16: 123-5.
153. Catarrala J, Fernández-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Excherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-60.
154. Cruciani M. Malena M, Bosco O. Nardi S, Serpelloni G, Mengoli C. Reappraisal with mcta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolonc in neutropenic patients. J Clin Oncol 2003; 21: 4127-37.
155. Bow E J, Mandell L A, Louie T J, Feld R. Palmer M, Zee B et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med 1996; 125: 183-90.
156. Prentice H G, Hann I M, Nazareth B, Paterson P. Bhamra A, Kibbler C C. Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol. 2001; 115:46-52. Erratum in: Br J Haematol 2002 Jun; 1 17 (4): 1002.
157. Gracia Escudero A, Martin González M, Giménez Garrido F, Clavero Faire C, García Pérez MJ, Álvarez Corral G. A prospective, controlled, non-randomized study of three cohorts to test the effectiveness of two antibiotics, Icvofloxacin and cotrimoxaz.ol on antibacterial prophylaxis in neutropenic patients. Med Clin (Bare) 2003; 120: 321-5.
158. De Pauw B. Preventativc use of antifungal drugs in patients treated for cancer. J Antimicrob Chemother 2004; 53: 130-2.
159. Goodman J E, Winston D J. Greenfield R A, Chandrasekar P H, Fox B, Kaizer H. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
160. Winston D, Chandrasekar P, Lazarus H. Goodman J, Silber J, Horowitz H, et al. Fluconazole prophylaxis infections in patients with acute leukemia. Ann Intern Med 1993; 1 18: 495-503.
161. Castagnola E. Machetti M. Bucci B, Viscoli C. Antifungal prophylaxis with azoles derivatives. Clin Microbiol Infect 2004; 10 Suppl 1: S86-95.
162. Comely O A, Bohme A. Buchheidt D, Glasmacher A, Kahl C, Karthaus M Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 Suppl 2: S186-200.
163. Glasmacher A, Prentice A, Gorschluler M, Engelhart S. Hahn C. Djulbegovic B, el al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignances. Evidence from a meta-analysis of 3597 patients. J Clin Oncol 2003; 21: 4615-26.
164. Harousseau J L. Dekker A W. Stamatoullas-Bastard A. Passas A, Linkesch W, Gouveia J, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itra-conazole and amphotcricin B. Antimicrob Agents Chernoter 2000; 44: 1887-93.
165. Sehwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, el al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized rnulticcnter trial. Blood 1999; 93: 3654-61.
166. Perfect J R, Klotman M E, Gilbert C C, Craw ford D D, Rosner G L, Wright K A. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891-7.
167. Mattiuzzi G, Estey E, Raad I, Giles F. Cortes J, Shen Y, et al. Liposomal amphotericin B versus the combination of fluconazolc and itraconazole as prophylaxis for invasive fungal infections during induction. Cancer 2003; 97: 450-6.
168. Golzsche P C, Johansen H K. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2002; (4): CD002033. Review.
169. Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 2004; 39 Suppl 1: S565-7.
170. Gershon A, Steinberg S. Persistence of immunity to varicella in children with leukemia inmunized with live attenuated varicella vaccine. N Eng J Med 1989; 320: 892-7.
171. Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 1987; 80: 465-72.
172. Varicella zoster immune globuline for the prevention of chickenpox. MMWR Morbid Mortal Wkly Rep 1984; 33: 84-90, 95-100.
173. Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicela in immunocompromised children. J Infect Dis 1988; 157: 309-13.
174. Asano Y, Yoshikawa T, Suga S, Kohayashi I, Nakashima T, Yazaki T, et al. Poslexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993; 92: 219-22.
175. Wagstaff A J, Faulds D, Goa K L. Acyclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 48: 199-226.